Poslední aktualizace :
18/04/2024
Antibiotikas   Amikacin sulfate  
Įpurškimas
Tirpalų stabilumas Mišinių stabilumas Stabilumą lemiantys veiksniai Suderinamumas Leidimo būdai Bibliografija Pdf
   Cheminė sandara  

Prekinis pavadinimas   Prekinis pavadinimas     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Adnet Indija
Agnicin Meksikas
Akamin Ekvadoras
Akim Ekvadoras
Amicacil Brazilija
Amicilon Brazilija
Amicin Malaizija
Amicip Venesuela
Amijeksin Turkija
Amikabiot Ekvadoras, Peru
Amikacin Didžioji Britanija, Egiptas, Iranas, Jungtinės Amerikos Valstijos, Kanada, Malaizija, Naujojoje Zelandijoje, Saudo Arabija, Vokietija
Amikacina Argentina, Čilė, Ekvadoras, Ispanija, Italija, Kolumbija, Meksikas, Peru, Venesuela
Amikacine Belgija, Marokas, Olandija, Prancūzija
Amikafur Meksikas
Amikagram Peru
Amikalem Meksikas
Amikamed Peru
Amikamek Peru
Amikan Italija
Amikavax Venesuela
Amikaver Turkija
Amikayect Meksikas
Amikem Peru
Amiketem Turkija
Amikin Airija, Australija, Brazilija, Didžioji Britanija, Egiptas, Ekvadoras, Jungtinės Amerikos Valstijos, Kolumbija, Lenkija, Meksikas, Peru, Saudo Arabija, Šveicarija, Tunisas, Vengrija
Amiklin Prancūzija, Turkija
Amikosit Rumunija, Tunisas, Turkija
Amikram Peru
Amukin Belgija, Liuksemburgas, Olandija
Apalin Malaizija
Baxi K Čilė, Meksikas
Behcacin Indija, Venesuela
Belka Indija
Biclin Austrija, Ispanija, Meksikas, Portugalija, Suomija, Švedija, Vokietija
Biodacyna Lenkija
Biokacin Meksikas
Briklin Graikija
Cadicin Indija
Chemacin Italija
Cikabit Indija
Cinamica Indija
Cinas Indija
Consumonit Graikija
Domak Indija
Doxocar Argentina
Elcin Indija
Elmik Indija
Emcin Indija
Emica Indija
Farcyclin Graikija
Flexelite Graikija
Greini Argentina
Ipacin Iranas
Itukacin Peru
Kancin Graikija
Lanomycin Graikija
Lukadin Italija
Masmika Indija
Mediamik Italija
Micalpha Graikija
Micigen Meksikas
Migracin Italija
Mikacin Saudo Arabija
Nekacin Italija
Novamin Brazilija
Orlobin Graikija
Remikin Graikija
Rovericlin Graikija
Uzix Graikija
Bibliografija   Įpurškimas   Bibliografija : Amikacin sulfate  
Tipas Leidinys
3 Žurnalas Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59 Žurnalas Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73 Žurnalas Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
84 Žurnalas Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Žurnalas Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104 Žurnalas Hall PD, Yui D, Lyons S, Bosso JA.
Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 185-189.
132 Žurnalas Najari Z, Rusho WJ.
Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.
Am J Health-Syst Pharm 1997 ; 54: 181-184.
169 Žurnalas Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Žurnalas Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
186 Žurnalas Swart EL, Mooren RAG, Van Loenen AC.
Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198 Žurnalas Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
244 Žurnalas Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 Žurnalas Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Žurnalas Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
253 Žurnalas Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528.
256 Žurnalas Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA.
Stability of fluconazole in commonly used intravenous antibiotic solutions.
Am J Hosp Pharm 1993 ; 50: 1206-1208.
280 Žurnalas Allen LV, Stiles ML, Prince SJ, Sylvestri MF.
Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
285 Žurnalas Elmore RL, Contois ME, Kelly J, Noe A, Poirier A.
Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs.
Clin Ther 1996 ; 18: 246-255.
299 Žurnalas Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Žurnalas Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Žurnalas Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Žurnalas Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
316 Žurnalas Veltri M, Lee CKK.
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.
Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
334 Žurnalas Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Žurnalas Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
336 Žurnalas Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409.
337 Žurnalas Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
367 Žurnalas Thompson DF, Allen LV, Desai SR, Rao PS.
Compatibility of furosemide with aminoglycoside admixtures.
Am J Hosp Pharm 1985 ; 42: 116-119.
384 Žurnalas Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 630-632.
385 Žurnalas Benedict MK, Roche VF, Banakar UV, Hilleman DE.
Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1117-1118.
386 Žurnalas Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
405 Žurnalas Nieves-Cordero AL, Luciw HM, Souney PF.
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1985 ; 42: 1108-1109.
434 Žurnalas Goodwin SD, Nix DE, Heyd A, Wilton JH.
Compatibility of ciprofloxacin injection with selected drugs and solutions.
Am J Hosp Pharm 1991 ; 48: 2166-2171.
472 Žurnalas Wohlford JG, Fowler MD.
Visual compatibility of hetastarch with injectable critical-care drugs.
Am J Hosp Pharm 1989 ; 46: 995-996.
491 Žurnalas Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184.
492 Žurnalas Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
496 Žurnalas Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
552 Žurnalas Martinez JF, Trissel LA, Gilbert DL.
Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions.
Int J Pharm Compound 1997 ; 1: 356-358.
561 Žurnalas Nunning BC, Granatek AP.
Physical compatibility and chemical stability of amikacin sulfate in large-volume parenteral solutions. Part II.
Current Ther Res 1976 ; 20: 359-368.
565 Žurnalas Marble DA, Bosso JA, Townsend RJ.
Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions.
Drug Intell Clin Pharm 1986 ; 20: 960-963.
575 Žurnalas Holmes CJ, Ausman RK, Kundsin RB, Walter CW.
Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags.
Am J Hosp Pharm 1982 ; 39: 104-108.
604 Laboratorija Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998
639 Žurnalas Zbrozek AS, Marble DA, Bosso JA, Bair JN, Townsend RJ.
Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes.
Drug Intell Clin Pharm 1987 ; 21: 806-810.
673 Žurnalas Bullock L, Clark JH, Fitzgerald JF, Glick MR, Hancock BG, Baenziger JC, Black CD.
The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures.
JPEN 1989 ; 13: 505-509.
905 Žurnalas Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Žurnalas Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
999 Žurnalas Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224.
1022 Žurnalas Hutchinson SMW.
Heparin and aminoglycosides instability.
Drug Intell Clin Pharm 1986 ; 20: 886.
1035 Žurnalas Bisaillon S, Sarrazin R.
Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion.
J Parenter Sci Technol 1983 ; 37: 129-132.
1047 Žurnalas Souney PF, Colucci RD, Mariani G, Campbell D.
Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1984 ; 41: 323-324.
1057 Žurnalas Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072 Žurnalas Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1201 Žurnalas Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG.
Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.
Am J Hosp Pharm 1981 ; 38: 1919-1922.
1315 Žurnalas Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410 Žurnalas Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Žurnalas Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Žurnalas Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1490 Žurnalas Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1625 Žurnalas Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1712 Žurnalas Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Žurnalas Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Žurnalas Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 Žurnalas Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1759 Žurnalas Servais H, Tulkens PM.
Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.
Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1800 Žurnalas Voytilla KL, Tyler LS, Rusho WJ.
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.
Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803 Žurnalas Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1816 Žurnalas Zhang Y, Trissel LA.
Stability of amikacin sulfate in autodose infusion system bags.
Int J Pharm Compound 2003 ; 7, 3: 230-232.
1868 Žurnalas Husson E, Crauste-Manciet S, Hadj-Salah E, ,Segier JC, Broissard D.
Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange.
Nutr Clin Metab 2003 ; 17: 8-14.
1925 Žurnalas Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Žurnalas Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Žurnalas Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2090 Žurnalas Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2109 Žurnalas Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75.
2141 Žurnalas Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658.
2231 Žurnalas de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247 Žurnalas Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 Žurnalas Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Žurnalas Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2296 Laboratorija Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
3012 Žurnalas Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3216 Žurnalas Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3249 Žurnalas Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3332 Laboratorija Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012
3385 Žurnalas Raverdi V, Ampe E, Hecq JD, Tulkens PM.
Stability and compatibility of vancomycin for administration by continuous infusion.
J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408 Žurnalas Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3522 Laboratorija Flucloxacillin - Summary of Product Characteristics.
Actavis 2013
3523 Laboratorija Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018
3526 Laboratorija Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010
3527 Laboratorija Amoxicillin (Amoxil®) – Summary of Product Characteristics
Glaxo Smith Kline 2018
3540 Laboratorija Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3543 Laboratorija Ceftazidime – Summary of Product Characteristics
Wockhardt 2013
3544 Laboratorija Cefoperazone (Cefobid®) - Summary of Product Characteristics
Pfizer 2006
3545 Laboratorija Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit
Mylan SAS 2009
3546 Laboratorija Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007
3548 Laboratorija Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007
3549 Laboratorija Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3578 Laboratorija Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3586 Laboratorija Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit
Actavis France 2010
3587 Laboratorija Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics
GlaxoSmithKline 2014
3594 Laboratorija Metronidazole (Flagyl®) - Summary of Product Characteristics
Zentiva 2013
3644 Laboratorija Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3656 Laboratorija Teicoplanine (Targocid®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2014
3674 Laboratorija Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3677 Laboratorija Cefpirome (Cefrom®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2008
3687 Laboratorija Cefuroxime sodium - Summary of Product Characteristics
Stravencon 2013
3728 Žurnalas Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766 Žurnalas Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3767 Žurnalas Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3791 Plakatas Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014
3824 Žurnalas Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3827 Plakatas Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Plakatas Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Plakatas So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3883 Laboratorija Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016
3964 Žurnalas Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4055 Žurnalas Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4319 Žurnalas Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4354 Plakatas Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables.
GERPAC Congress 2019 2019
4380 Laboratorija Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019
4389 Žurnalas Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4419 Žurnalas Holt R.J, Siegert S.W.K, Krishna A.
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4524 Plakatas Stucki C, Sautter A-M, Bonnabry P.
Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology.
ESCP Symposium, Geneva, Switzerland 2009
4528 Žurnalas Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4603 Žurnalas Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4650 Laboratorija Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4654 Plakatas Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.
Communication personnelle 2021
4742 Žurnalas Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales